ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Diethylpropion (Amfepramone). Tolerance to diethylpropion’s anorexiant action usually develops within a few weeks. When tolerance to the anorexiant action is noted, discontinue diethylpropion pharmacotherapy. Diethylpropion is indicated only for short-term adjunctive pharmacotherapy for weight loss among obese patients who also are receiving appropriate psychotherapy, caloric restriction, and other appropriate treatment. Diethylpropion is a CNS stimulant sympathomimetic amine pharmacologically derived from the amphetamines. Actions include CNS stimulation and elevation of blood pressure. Diethylpropion also has been associated with tachyphylaxis and tolerance. Long-term diethylpropion pharmacotherapy, or regular personal use, may result in addiction and habituation. Diethylpropion is chemically and pharmacologically related to the amphetamines, which have high abuse potential. Signs and symptoms of acute diethylpropion overdosage include convulsions, drowsiness, exhaustion, insomnia, irritability, nervousness, and tachycardia.
